title: Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.
abstract: The clonal B-cell immunoglobulin idiotype found on the surface of lymphomas was the first targeted tumor-specific antigen, and combinations of idiotype with classical and novel adjuvants were shown to stimulate robust humoral and cellular responses, though clinical efficacy was more variable. Cellular and in situ vaccination to help target a wider array of tumor-specific antigens have also been able to stimulate tumor-specific cellular responses, though their clinical success has also been limited. Our growing understanding of the role of regulatory cells and the immunosuppressive tumor microenvironment, along with a wide variety of immunomodulatory agents developed as of late, offer promising adjuvants to potentiate the immune responses elicited by these vaccine protocols and to achieve durable remissions.
authors.affiliation: Division of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Thomas U
authors.initials: TU
authors.lastname: Marron
authors.affiliation: Division of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Lukas
authors.initials: L
authors.lastname: Ronner
authors.affiliation: Division of Hematology & Medical Oncology, Meyer Cancer Center, Weill Cornell Medical College, New York, NY, USA.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Martin
authors.affiliation: Department of Hematology & Medical Oncology, Emory University, Atlanta, GA, USA.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Flowers
authors.affiliation: Division of Hematology & Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Brody
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D059016:Tumor Microenvironment
chemical_list: D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes
keywords: cancer vaccine; immunotherapy; lymphoma